JPRN-UMIN000003703Recruiting未知
Phase I trial of Cetuximab combined with S-1 and irrinotecan in advanced colorectal cancer - Phase I trial of Cetuximab combined with S-1 and irrinotecan in advanced colorectal cancer
Toho University school of Medicine0 sites10 target enrollmentStarted: June 7, 2010Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- Enrollment
- 10
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1. Multiple malignancies 2. Serious complications(intestinal paralysis and intestinal obstruction, interstitial pneumonia, pulmonary fibrosis,renal failure, cardiac failure , liver failure) 3.Infection 4.Diarrhea 5. mechanical bowel obstruction 6.Uncontrolable pleural effusion or ascites requiring 7.History of serious drug hypersensitivity 8.Need to treatment with flucytosine, atazanavir sulfate 9.Fresh bleeding of digestive organs 10.Cirrhosis, Icterus 11.Evidence of psychiatric disability interfering with enrollment to clinical trial 12.Need to treatment with heart failure, ischemic heart disease or arrhythmia 13.Uncontrolable diabetes 14.Symptomatic brain metastasis 15.Pregnant or lactating women or women of childbearing potential. 16.Patients judged inappropriate for this study by physicians
Investigators
Similar Trials
Recruiting
Phase 1
Phase I/II study of Cetuximab combined with S-1 and irrinotecan (CeIRIS) in KRAS wild type metastatic colorectal cancer patients refractory to treatment with oxaliplatin and fluoropyrimidine.Colorectal cancer: KRAS wild typeJPRN-UMIN000003288Kyushu Medical Oncology Group40
Completed
Phase 2
Phase II trial of S-1 plus Cetuximab combination therapy in patients inappropriate for platinum-based therapy with recurrent/metastatic squamous cell carcinoma of the head and neckJPRN-UMIN000015123Hokkaido University21
Completed
Phase 2
Phase II trial of S-1 plus Cetuximab combination chemotherapy for advanced recurrent/metastatic carcinoma of the oral cavityAdvanced recurrent/metastatic carcinoma of the oral cavityJPRN-UMIN000024371Osaka University20
Recruiting
Phase 1
Phase1 trial of Cetuximab/S-1 combination therapy for Advanced/Recurrent Colorectal CancerJPRN-UMIN000004124Kinki university school of medicine Department of clinical oncology21
Not yet recruiting
Phase 1
Phase I/II trial of S-1+Nedaplatin+Cetuximab for recurrent/metastatic head and neck squamous cell carcinomahead and neck squamous cell carcinomaJPRN-UMIN000012074Kyorin University School of Medicine, Department of Otolaryngology30